Biomarkers Help Diagnose Mild Cognitive Impairment in Diabetics
By LabMedica International staff writers Posted on 02 Mar 2016 |
Image: Dot blots showing the expressions of total glycogen synthase kinase-3β (tGSK-3β) and p-GSK-3β (ser9) in the platelets; the differences of platelet GSK-3β activity between T2DM-nMCI group and T2DM-MCI group (Photo courtesy of Tongji Medical College).
Alzheimer's disease is the most common cause of senile dementia, and the prevalence is increasing with population aging and even when the clinical diagnosis of Alzheimer's disease is made, it is generally too late to be curable.
Type 2 diabetes mellitus (T2DM) is also an age-associated disorder, and the patients with T2DM show a significantly increased risk to suffer from Alzheimer's disease. Biomarkers that can diagnose or predict conversion of T2DM into Alzheimer's disease would make it possible to start an early intervention, and eventually reduces the incidence of Alzheimer's disease.
Scientists at the Huazhong University of Science and Technology (Wuhan, China) and their colleagues recruited 646 T2DM patients from January 2012 to May 2015 from five hospitals. Patients in each set were randomly divided into two groups: T2DM without mild cognitive impairment (MCI) (termed T2DM-nMCI) or with MCI (termed T2DM-MCI). Glycogen synthase kinase-3β (GSK-3β) activity in platelets, ApoE genotypes in leucocytes and the olfactory function were detected by Western/dot blotting.
For biochemical indicators, all participants were asked to measure fasting blood glucose, postprandial blood glucose, serum insulin, hemoglobinA1c (HbA1c) and serum magnesium, the next morning. On receipt, serum, leukocytes and platelet samples were separated from EDTA whole blood by centrifugation, which were collected and stored at -80 °C until analysis. The total GSK-3β (tGSK-3β) and serine-9 phosphorylated GSK-3β (pS9GSK-3β, the inactive form of the kinase) in serum or platelet were measured by ELISA (Cusabio Biotech Co., Ltd.; Wuhan, China), Western blotting or dot blotting. In addition, the biochemical activity of GSK-3β in platelet was measured by using enzyme activity assay kit.
The scientists found no significant differences for sex, T2DM years, hypertension, hyperlipidemia, coronary disease, complications, insulin treatment, HbA1c, ApoE ε2, ApoE ε3, tGSK3β and pS9GSK3β between the two groups. They did find that that activation of the peripheral circulating GSK-3β, expression of ApoE ε4, dysfunction of the olfactory function, and aging are diagnostic for the mild cognitive impairment in T2DM patients, and combination of these factors can significantly improve the diagnostic accuracy. They also developed a simple protocol for measuring the total and the inactivated form of GSK-3β in human platelets. As the method is simple and easy to operate with low cost and good repeatability, it is suitable for application in clinical laboratories.
Jian-Zhi Wang, PhD, a professor and senior author of the study, said, “Although we have designed training set and validation set respectively to assure the correlation of cognitive impairments with the biomarkers, further longitudinal studies are needed to confirm how informative these biomarkers in predicting the conversion of T2DM into Alzheimer's disease.” The study was published on February 13, 2016, in the journal EbioMedicine.
Related Links:
Huazhong University of Science and Technology
Cusabio Biotech
Type 2 diabetes mellitus (T2DM) is also an age-associated disorder, and the patients with T2DM show a significantly increased risk to suffer from Alzheimer's disease. Biomarkers that can diagnose or predict conversion of T2DM into Alzheimer's disease would make it possible to start an early intervention, and eventually reduces the incidence of Alzheimer's disease.
Scientists at the Huazhong University of Science and Technology (Wuhan, China) and their colleagues recruited 646 T2DM patients from January 2012 to May 2015 from five hospitals. Patients in each set were randomly divided into two groups: T2DM without mild cognitive impairment (MCI) (termed T2DM-nMCI) or with MCI (termed T2DM-MCI). Glycogen synthase kinase-3β (GSK-3β) activity in platelets, ApoE genotypes in leucocytes and the olfactory function were detected by Western/dot blotting.
For biochemical indicators, all participants were asked to measure fasting blood glucose, postprandial blood glucose, serum insulin, hemoglobinA1c (HbA1c) and serum magnesium, the next morning. On receipt, serum, leukocytes and platelet samples were separated from EDTA whole blood by centrifugation, which were collected and stored at -80 °C until analysis. The total GSK-3β (tGSK-3β) and serine-9 phosphorylated GSK-3β (pS9GSK-3β, the inactive form of the kinase) in serum or platelet were measured by ELISA (Cusabio Biotech Co., Ltd.; Wuhan, China), Western blotting or dot blotting. In addition, the biochemical activity of GSK-3β in platelet was measured by using enzyme activity assay kit.
The scientists found no significant differences for sex, T2DM years, hypertension, hyperlipidemia, coronary disease, complications, insulin treatment, HbA1c, ApoE ε2, ApoE ε3, tGSK3β and pS9GSK3β between the two groups. They did find that that activation of the peripheral circulating GSK-3β, expression of ApoE ε4, dysfunction of the olfactory function, and aging are diagnostic for the mild cognitive impairment in T2DM patients, and combination of these factors can significantly improve the diagnostic accuracy. They also developed a simple protocol for measuring the total and the inactivated form of GSK-3β in human platelets. As the method is simple and easy to operate with low cost and good repeatability, it is suitable for application in clinical laboratories.
Jian-Zhi Wang, PhD, a professor and senior author of the study, said, “Although we have designed training set and validation set respectively to assure the correlation of cognitive impairments with the biomarkers, further longitudinal studies are needed to confirm how informative these biomarkers in predicting the conversion of T2DM into Alzheimer's disease.” The study was published on February 13, 2016, in the journal EbioMedicine.
Related Links:
Huazhong University of Science and Technology
Cusabio Biotech
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans